Full-Time
Confirmed live in the last 24 hours
Biotechnology company for early cancer detection
$173.8k - $263.2k/yr
Senior
Daly City, CA, USA
Hybrid role based in Brisbane, California headquarters (2-3 days per week in office) or remote.
Freenome focuses on improving cancer detection through advanced blood tests. The company uses a multiomics approach, analyzing various biological data types, including genomics and proteomics, to find cancer markers in the blood. Its primary clients are healthcare providers and research institutions, and it generates revenue by selling these non-invasive diagnostic tests. Freenome is also involved in clinical trials and research collaborations. Recently, it secured $270 million in funding to enhance its colorectal cancer blood test and expand clinical trials. The company aims to foster a collaborative culture and prioritize diversity, equity, and inclusion while driving innovation in cancer diagnostics.
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$1.1B
Headquarters
San Francisco, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Competitive market-based salaries
Annual bonus opportunities
Relocation packages
Medical, dental, & vision coverage
401k
Wellness programs
Equity
PTO
Accomplished industry leader brings specialized experience to advance Freenome's screening blood tests for colorectal cancer, lung cancer and additional indications BRISBANE, Calif., April 8, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron Elliott, Ph.D., as its new chief executive officer. With nearly 20 years in the diagnostics industry, Aaron has provided leadership at the intersection of RD, product development and commercialization to drive market traction and expand clinical impact. His experience includes a deep focus on early cancer detection and multiomics that aligns with Freenome's mission to make cancer screening accessible for everyone
Cancer testing company Freenome to lay off 100 employees.
The announcement comes alongside two ongoing clinical trials launched by Freenome, including its prospective PREEMPT CRC study (NCT04369053), a longitudinal real-world data study consisting of under 40,000 participants evaluating the company's blood-based screening test among adults at average risk for CRC.
Roche led the financing alongside existing and new investors. The funds will progress clinical programs and expand platform capabilities.
– Registrational study targets enrollment of 20,000 individuals at high risk of lung cancer –SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 /PRNewswire/ -- Freenome, a privately held company developing multiomics blood tests for early cancer detection, today announced the initiation of its PROACT LUNG study and provided an update on its lung cancer research, including the ongoing Vallania study. The study is intended to validate the clinical performance of the Freenome blood test for lung cancer screening. The test combines lung cancer-specific biomarkers with cancer-common markers identified on Freenome's proprietary multiomics platform. This is Freenome's second blood-based test developed on the platform and being evaluated in a prospective clinical study.Early detection of lung cancer, while in its most treatable stage, leads to better clinical outcomes for patients.1,2 Recently, the United States Preventive Services Task Force expanded the recommended ages and smoking history for lung cancer screenings, reaffirming the importance of early detection. In people at high risk for lung cancer, annual screening with a low-dose CT (LDCT) scan is typically recommended as part of the standard of care (SOC)